The Future of mRNA Platforms: Strategic Pause or Premature Pivot?

Manica Negahdaripour

PMC · DOI:10.30476/ijms.2025.108672.4367·October 1, 2025

The Future of mRNA Platforms: Strategic Pause or Premature Pivot?

Manica Negahdaripour

PDF

Open Access

Abstract

Linked entities

Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.

Genes1

S

Proteins1

Species2

Severe acute respiratory syndrome coronavirus 2(no rank)Homo sapiens(human · species)

Diseases11

death influenza respiratory infections COVID-19 non-small cell lung cancer infection genetic diseases myocarditis measles melanoma cancer

Peer Reviews

No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.

Videos

No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.